Can the COVID-19 Vaccine Cause Lupus?

A handful of case reports describe people developing lupus shortly after receiving a COVID-19 vaccine, but large-scale safety databases covering millions of vaccine recipients have found no statistical link between COVID-19 vaccination and lupus. The gap between individual case reports and population-level data is the crux of this question, and understanding it matters whether you are healthy and worried about autoimmunity or already living with lupus and weighing the risks of a booster.

What the Case Reports Actually Show

As of the early literature reviews, at least eight cases of new-onset systemic lupus erythematosus (SLE) had been documented following COVID-19 vaccination. Most of these patients were women, and the majority were in their thirties. About two-thirds of the cases appeared after the first dose, while the rest followed the second dose.¹ One early report from the Mayo Clinic described what was believed to be the first case of lupus occurring after an mRNA vaccine specifically, noting that two earlier cases had involved viral-vector vaccines instead.²

These reports also extend beyond classic systemic lupus. A case of a 15-year-old boy developing a rare linear form of cutaneous lupus on his arm about a month after his second COVID-19 vaccine dose was described as the first of its kind.³ A pediatric case involved a 14-year-old boy who developed full-blown SLE, including kidney involvement, just two days after his third Pfizer dose, though his symptoms improved with standard lupus treatment.⁴

Eight or even a few dozen cases across billions of vaccine doses is extraordinarily rare. But case reports like these are how medicine first identifies potential signals, so they have been taken seriously as a starting point for larger investigations.

What Large-Scale Safety Data Say

When researchers move beyond individual stories and look at vaccine safety databases covering millions of people, the signal disappears. An analysis of the VAERS database spanning 1990 to 2025, which contains over 11 million adverse-event reports, identified 1,976 cases of vaccine-associated lupus across all vaccines combined. That works out to roughly 0.017% of all reported adverse events. The analysis specifically noted that COVID-19 vaccines, along with influenza and shingles vaccines, showed no relationship with lupus or lupus-related organ involvement.⁵

European safety data tell the same story. A disproportionality analysis of European adverse-event reports found no statistically significant associations between COVID-19 vaccination and lupus-related conditions.⁶ This kind of analysis looks for whether lupus reports are unusually common among COVID-19 vaccine recipients compared to what you would expect by background rates. They were not.

The discrepancy between alarming case reports and reassuring population data is not unusual in medicine. Lupus develops in roughly 5 out of every 100,000 people each year. With billions of vaccine doses administered, some people will inevitably develop lupus in the weeks after vaccination simply by coincidence. A temporal association, where event B happens after event A, does not establish causation. The pharmacovigilance data suggest that COVID-19 vaccines are not increasing that background rate.

How Vaccines Could Theoretically Trigger Autoimmunity

Even though the population data are reassuring, the biological mechanisms by which a vaccine might occasionally push a predisposed immune system toward autoimmunity are real and worth understanding. Researchers have outlined several pathways.

The most discussed is molecular mimicry. Parts of the SARS-CoV-2 spike protein share structural similarities with certain human proteins. When the immune system learns to attack the spike protein, it could theoretically generate antibodies that also react against the body’s own tissues. Computational studies have identified mimicry “hotspots” in the spike protein with potential autoimmune implications.⁷ This same mechanism applies to natural COVID-19 infection, where the immune system encounters the full virus rather than just the spike protein, giving it even more opportunities for cross-reactivity.

A second pathway involves bystander activation, where the strong immune response triggered by the vaccine nonspecifically activates immune cells that happen to target the body’s own tissues. Both molecular mimicry and bystander activation have been described as potential contributors to vaccine-triggered autoimmune phenomena.⁸

A third mechanism specific to mRNA vaccines involves the lipid nanoparticle carrier that delivers the mRNA into cells. The ionizable lipid in these carriers has been shown to act as an adjuvant, triggering immune-signaling molecules including type I interferons. This is relevant to lupus specifically because type I interferon overactivity is a hallmark of lupus biology.⁹ People with lupus already have elevated interferon activity, so an additional interferon boost from vaccination could theoretically nudge disease activity upward.

Genetic factors also seem to play a role in who is vulnerable. Certain HLA gene variants, which shape how the immune system recognizes threats, have been linked to vaccine-associated autoimmune conditions. While the specific HLA associations studied so far relate more to conditions like thyroiditis and vaccine-induced thrombocytopenia than to lupus itself, they underscore that genetic background matters in determining who might react abnormally.¹⁰

Do COVID-19 Vaccines Change Autoantibody Levels?

One way to test whether vaccines are nudging the immune system toward lupus is to measure autoantibodies, the self-targeting antibodies that are a hallmark of the disease, before and after vaccination in healthy people. The results here are mixed and depend heavily on the vaccine type studied.

A study of the Pfizer-BioNTech mRNA vaccine found no meaningful change in antinuclear antibody (ANA) or antiphospholipid antibody levels after vaccination. About 9% of participants tested ANA-positive before their shots, and the rate actually dipped slightly afterward.¹¹ A larger study of 357 people found that ANA positivity was about 45% before vaccination and 47% after, a difference that was not clinically significant.¹²

Inactivated vaccines, however, told a somewhat different story. One study found that inactivated COVID-19 vaccines increased the rate of anti-dsDNA antibody positivity from about 14% to 36%, a statistically significant jump. The mRNA vaccine in that same study did not produce a similar increase. People who received both types of vaccine saw the highest increase, with anti-dsDNA positivity rising from 20% to over 53%.¹³ Anti-dsDNA antibodies are among the most specific markers for lupus, so this finding is notable, though having detectable autoantibodies does not mean someone will develop disease.

The overall picture from autoantibody studies is that mRNA vaccines appear to have minimal impact on lupus-related autoantibodies in healthy people, while inactivated vaccines may transiently raise some markers. Whether these transient antibody changes translate into actual disease risk is unknown, and the large pharmacovigilance studies described earlier suggest that if they do, it happens extremely rarely.

Flares in People Who Already Have Lupus

For people already living with lupus, the more pressing question is not “will the vaccine give me lupus” but “will it make my lupus worse?” This has been studied more thoroughly, and the answer is nuanced.

About half of lupus patients experience some kind of adverse effect after COVID-19 vaccination, though these are mostly the same short-lived reactions everyone gets: sore arm, fatigue, low-grade fever. In most cases, they do not interfere with daily life.¹⁴

Actual lupus flares, meaning measurable increases in disease activity, do occur. In one detailed study, flares appeared after the first, second, and third vaccine doses in roughly 9%, 20%, and 18% of patients respectively. The flares ranged from mild to severe, with the most commonly affected systems being the skin (new rashes or hair loss), blood (low white blood cell counts), and kidneys (increased protein in the urine).¹⁵

The critical context comes from comparing these rates to what happens without vaccination. A study of 449 vaccinated lupus patients matched against an equal number of unvaccinated patients found that flare rates were not meaningfully different between the two groups. About 8% of vaccinated patients flared versus 6% of unvaccinated patients, a difference that was not statistically significant.¹⁶ Lupus is a disease that flares and remits on its own, so some patients will experience flares in the weeks following any event, vaccination included. The matched-control design helps separate vaccine-caused flares from coincidental ones, and the data suggest most post-vaccination flares fall into the coincidental category.

Does the Vaccine Type Matter?

COVID-19 vaccines came in several forms: mRNA (Pfizer, Moderna), viral vector (AstraZeneca, Johnson & Johnson), and inactivated virus (Sinovac, Sinopharm). Given the different ways these platforms stimulate the immune system, it is reasonable to wonder whether some are riskier for lupus patients than others.

A comparative study across vaccine platforms found that the incidence rate of flares per 100 patient-months was not significantly different among the vaccine types. The rates were roughly comparable across mRNA, viral vector, and inactivated platforms.¹⁷ This is somewhat surprising given the differences in how these vaccines work, but it suggests that the flare risk for lupus patients is not strongly driven by the specific platform.

The autoantibody data discussed earlier do show some divergence between platforms, with inactivated vaccines potentially raising anti-dsDNA levels more than mRNA vaccines. But since flare rates are comparable across types and the population data show no lupus signal for any platform, the practical takeaway is that no single vaccine type stands out as particularly dangerous for lupus patients.

How Lupus Medications Affect Vaccine Response

If you have lupus and are taking immunosuppressive medications, a different concern arises: not that the vaccine will harm you, but that it may not work well enough. Multiple studies have found that common lupus medications substantially reduce the antibody response to COVID-19 vaccination.

Lupus patients on immunosuppressive drugs produced lower vaccine antibody levels than lupus patients not taking them, and both groups had lower levels than healthy people. Mycophenolate, tacrolimus, and belimumab all significantly reduced the antibody response.¹⁸ Patients taking conventional or biologic disease-modifying drugs showed reduced neutralizing antibody responses compared to patients taking hydroxychloroquine alone.¹⁹

Rituximab, a drug that depletes B cells, was particularly impactful. Among lupus and rheumatoid arthritis patients treated with rituximab, only about a quarter had detectable antibodies after vaccination.²⁰ This does not mean the vaccine provides zero protection since T-cell immunity, which these antibody tests do not measure, can still offer defense against severe illness. But it does mean lupus patients on strong immunosuppression may be less protected than they expect.

The American College of Rheumatology has issued guidance on timing immunosuppressive medications around vaccination to maximize the immune response, though the task force acknowledged a lack of direct evidence and relied on expert consensus.²¹ In practice, this often means holding mycophenolate for a week or two after each dose, or timing rituximab infusions to allow a window for vaccination, depending on the specific drug and disease activity. These are conversations best had with a rheumatologist who knows your particular situation.

COVID-19 Infection Versus Vaccination

One piece of context that often gets lost in these discussions is that SARS-CoV-2 infection itself carries autoimmune risk, likely greater than the vaccine’s. The virus presents the immune system with the full complement of viral proteins, not just the spike, creating more opportunities for molecular mimicry and cross-reactive antibody production. The intense, uncontrolled inflammation of COVID-19 is also a well-recognized trigger for autoimmune conditions. Multiple autoimmune diseases, lupus among them, have been reported following natural COVID-19 infection.⁸

For lupus patients specifically, COVID-19 infection poses the additional threat of triggering severe flares, kidney damage, and blood-clotting complications. The consensus among rheumatology professional organizations has consistently been that the benefits of vaccination outweigh the small risk of a post-vaccine flare, precisely because the alternative, unvaccinated exposure to the virus, is likely worse for lupus patients than for the general population.

The Role of Genetic Susceptibility

The handful of people who do develop new autoimmune conditions after vaccination are probably not random. Lupus has a strong genetic component, and the reported post-vaccine cases tend to fit the demographic profile of spontaneous lupus: predominantly young women, often with family histories of autoimmune disease. One case-report review noted that three-quarters of the new-onset SLE cases following vaccination were female, and the majority were in their third decade of life, which mirrors the typical age and sex distribution of lupus.¹

Researchers studying the environmental triggers of autoimmunity have long recognized that infections, medications, ultraviolet light, and hormonal changes can all serve as the final push in someone whose immune system is already primed for self-attack. It is plausible that in extremely rare instances, the immune activation from a vaccine serves as one of these triggers. Genetic factors, hormonal factors, and environmental exposures are all understood to contribute to autoimmune disease, with infectious agents and vaccinations acting as potential triggers in genetically predisposed individuals.²² The vaccine would not be creating lupus from nothing but rather unmasking a process that was likely to emerge eventually.

Drug-Induced Lupus and How It Differs

Some confusion arises because the medical literature uses the term “drug-induced lupus” to describe lupus-like symptoms triggered by medications. Classic drug-induced lupus, most commonly associated with drugs like hydralazine and procainamide, behaves differently from spontaneous SLE. It tends to be milder, rarely involves the kidneys, and typically resolves when the triggering drug is stopped.

Whether the post-vaccine lupus cases represent true SLE being unmasked or a drug-induced-lupus-like reaction to the vaccine components is still debated. Some of the reported cases included serious organ involvement like kidney disease, which is more characteristic of genuine SLE than of drug-induced lupus. The distinction matters clinically because drug-induced lupus usually goes away on its own, while true SLE requires long-term management. For patients and their doctors, the practical step is the same regardless: treat the symptoms present and monitor closely.

Vaccine Hesitancy Among Lupus Patients

Fear of flares has been a real barrier to vaccination among people with lupus. This hesitancy is understandable: when you have a disease characterized by an overactive immune system, deliberately provoking an immune response feels counterintuitive. Early in the vaccine rollout, lupus patients were largely excluded from clinical trials, which left them without clear safety data specific to their condition.

The evidence that has accumulated since then generally supports vaccination. Flare rates after vaccination are close to background rates seen in unvaccinated lupus patients.¹⁶ Severe flares do occur but are uncommon. The American College of Rheumatology has maintained its recommendation that lupus patients receive COVID-19 vaccination, with appropriate timing around immunosuppressive medications.²³ The guidance acknowledges that direct evidence is limited and leans on expert consensus, but the direction of the recommendation has been consistent across multiple updates.

For people without a lupus diagnosis who worry that the vaccine might trigger the disease from scratch, the pharmacovigilance data offer the most relevant reassurance. Across hundreds of millions of COVID-19 vaccine doses tracked in the US and Europe, lupus has not emerged as a vaccine-associated condition at the population level. The case reports, while medically interesting and important for ongoing surveillance, represent a frequency so low that it is difficult to separate from background incidence.